Pluri Inc PLUR

Healthcare Biotechnology

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It ...

NDAQ:PLUR - Post by User

Pluri Inc

<< Previous

Bullboard Posts

Next >>

(76)
•••

Post by lucaM1on Apr 04, 2022 11:54am

68 Views

Post# 34573282

Cell Expansion Market To Reach Value Of USD 39.74 Billion

The global cell expansion market is estimated to reach value of USD 39.74 Billion by 2027, according to a current analysis by Emergen Research. Cell expansion is witnessing a surge in demand owing to an increase in automated solutions. Automation in the production of gene therapies and cell therapies products reduces the cost of production and decreases workforce.

As a company that both develops cell therpay treatments and uses its cell expansion technology to create different cell based products, Pluristem can be a key player in the market for years to come.

<< Previous

Bullboard Posts

Next >>

Canada advances Arctic defence with new military satellite communications project